

December 7, 2021

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Establishes a Local Subsidiary in Malaysia

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has established a local subsidiary in Malaysia as of December 7, 2021, as a wholly owned subsidiary of Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. (hereinafter, "SPAP") which is a wholly owned subsidiary of Sumitomo Dainippon Pharma.

In Malaysia, Sumitomo Dainippon Pharma is currently selling MERONEM[®] (generic name: meropenem hydrate, brand name in Japan: MEROPEN[®]), a carbapenem antibiotic, through a local partner company and plans to launch LATUDA[®] (generic name: lurasidone hydrochloride), an atypical antipsychotic currently under regulatory review in 2022. Sumitomo Dainippon Pharma aims to further strengthen ties with local partner companies and establish its own sales system for future new products including LATUDA[®] with the establishment of this local subsidiary. The new company to be set up in Malaysia will also oversee the medical affairs operation in Asia (excluding Japan and China), which is responsible for maximizing the value of products under development and commercialized products through generation and dissemination of evidence to fulfill unmet medical needs.

Sumitomo Dainippon Pharma has local subsidiaries in China, Singapore, Thailand and Taiwan, and a representative office in Vietnam, thus showing its commitment to Asia, a growing market for pharmaceuticals. With the establishment of this new subsidiary, Sumitomo Dainippon Pharma aims to maximize the value of its products launched in Malaysia and further strengthen its business foundation in Asia.

Reference

Outline of the local subsidiary in Malaysia

Company name	Sumitomo Pharma Malaysia Sdn. Bhd.
Establishment	December 7, 2021
Representative	Yoshitaka Koketsu
Share capital	2 million Malaysian ringgit (approx. 54 million yen*)
Number of employees	11
Functions	Sale of ethical drugs, and provision and collection of product information, medical and scientific information to and from medical professionals in Malaysia
Ownership	SPAP
Location	Kuala Lumpur

*Calculated with a rate of 1 Malaysian ringgit = 27 yen

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)